Celyad Oncology Sa (CYAD) Return on Investment ROI from the fourth quarter of 2022 to fourth quarter of 2021 and for the year 2022, average high and low, overall ranking from Dec 31 2022 to Dec 31 2021 - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• ROA Quarterly
• ROI Quarterly
• ROE Quarterly
Celyad Oncology Sa  (NASDAQ: CYAD)


Celyad Oncology Sa's ROI from its fourth quarter of 2022 to the fourth quarter of 2021 and 5 Year Period

Return on Investment, Quarterly Results, Trends, Rankings, Statistics

What is Celyad Oncology Sa's ROI in the fourth quarter of 2022?
Celyad Oncology Sa recorded a cumulative net loss of $-46 million during 12 months ending in the fourth quarter of 2022, resulting in a negative return on investment (ROI) of -841.19%.

Within the Healthcare sector 1145 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the third quarter of 2022 from 0 to 5816.

Definition and Formula of Return on Investment


Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

Return On Investment (Dec 31 2022)
IV. Quarter		 0
III. Quarter		 0
II. Quarter		 0
I. Quarter		 (Dec 31 2021)
IV. Quarter
Y / Y Investment Change TTM -90.63 % -93.28 % -69.1 % -42.81 % -10.31 %
Y / Y Net Income Change TTM - - - - -
Investment (TTM) in Millions 7 5 5 5 5
Return On Investment (TTM) -841.19 % -585.69 % -132.06 % -74.76 % -51.03 %
CYAD's Overall Ranking # 5816 # 0 # 0 # 0 # 0
Seq. Investment Change TTM 7.5 % -77.45 % -43.39 % -31.75 % -22.85 %
Seq. Net Income Change TTM - - - - -
Net Income (TTM) in Millions -46 -30 -30 -30 -30

CYAD Company Profile >> Back to CYAD Roi Comparisons >> See Annual CYAD Return On Investment



Return On Investment CYAD's Ranking
Within: No.
Industry # 564
Sector # 1146
Overall # 5816

Return On Investment Statistics
High Average Low
-31.71 %
-186.7 %
-894.75 %
(Dec 31 2020)   (Dec 31 2022)







Financial Statements
Celyad Oncology Sa's IV. Quarter Investments $ 7 Millions CYAD's Balance sheet
Celyad Oncology Sa's IV. Quarter Income $ -46 Millions Quarterly CYAD's Income Statement
CYAD's Income by Division See CYAD's Income by Division


CYAD Annual Return On Investment (Dec 31 2022)
2022		 (Dec 31 2021)
2021		 (Dec 31 2020)
2020		 (Dec 31 2019)
2019		 (Dec 31 2018)
2018
Total Investments in Millions 5 75 64 87 96
Y / Y Investment Growth -93.42 % 16.59 % -26.82 % -9.19 % -28.6 %
Net Income in Millions -43 -31 -20 -32 -44
Y / Y Net Income Growth - - - - -
Annual Return On Investment -878.74 % -42.06 % -30.7 % -36.68 % -45.96 %


Annual Roi Comment


Definition and Formula of Return on Investment

Other ROI Ratios
Major Pharmaceutical Preparations Industry Roi Trends and Statistics
Healthcare Sector Return On Investment Statistics
Roi Trends for overall market
CYAD's Roi Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Return On Investment
Lowest Ranking Return On Investment
Subscribers only: Roi for CYAD's Competitors
Subscribers only: Roi for Celyad Oncology Sa's Suppliers
Subscribers only: Return On Investment for CYAD's Customers

Other Ratios
CYAD's Roa CYAD's Inventory Turnover Ratio CYAD's Growth Rates CYAD's Dividend Statistics
CYAD's Profitability Ratios CYAD's Asset Turnover Ratio CYAD's Dividend Growth
CYAD's Roe CYAD's Valuation Ratios CYAD's Financial Strength Ratios CYAD's Dividend Payout Ratio



Companies with similar Return On Investment at Dec 31 2022, within Healthcare Sector ROI

Date modified: 2026-06-22T17:07:46+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.